α-Difluoromethylornithine as treatment for metastatic breast cancer patients

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3438-3444

  O'Shaughnessy, Joyce A ^a,c   Demers, Laurence M ^b   Jones, Stephen E ^a   Arseneau, James ^a   Khandelwal, Pankaj ^a   George, Timothy ^a   Gersh, Robert ^a   Mauger, David ^b   Manni, Andrea ^b  

^a TEXAS ONCOLOGY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; ORNITHINE DECARBOXYLASE; POLYAMINE; PUTRESCINE; SPERMIDINE; SPERMINE; TUMOR MARKER;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METASTASIS; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EFLORNITHINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYAMINES; PUTRESCINE; RECEPTORS, ESTROGEN; SPERMIDINE; SPERMINE; TIME FACTORS;

EID: 0032713928     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cold, S., Jensen, N. V., Brincker, H., and Rose, C. The influence of chemotherapy on survival after recurrence in breast cancer - a population-based study of patients treated in the 1950's, 1960's, and 1970's. Eur. J. Cancer, 29A: 1146-1152, 1993.
2. Pegg, A. E. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem. J., 234: 249-262, 1986.
3. Pegg, A. E. Polyamine metabolism and its importance in neoplastic growth and as target for chemotherapy. Cancer Res., 48: 759-774, 1988.
4. Manni, A. The role of the polyamine pathway in breast cancer development, progression and proliferation. A possible target for anti-tumor therapy. Endocrine-Related Cancer, 2: 141-151, 1995.
5. Manni, A. The role of polyamines in the hormonal control of breast cancer cell proliferation. In: R. Dickson and M. Lippman (eds), Mammary Tumorigenesis and Malignant Progression, pp. 209-225. Norwell, MA: Kluwer Academic Publishers, 1994.
6. Manni, A., Grove, R., Kunselman, S., and Aldaz, M. Involvement of the polyamine pathway in breast cancer progression. Cancer Lett., 92: 49-57, 1995.
7. Manni, A., Mauger, D., Gimothy, P., and Badger, B. Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin. Cancer Res., 2: 1901-1906, 1996.
8. Oredsson, S. M., Nicander, B., and Heby, O. Implications for a reduced DNA-elongation rate in polyamine-depleted cells. Eur. J. Biochem., 190: 483-489, 1990.
9. Glikman, P., Manni, A., Demers, L., and Bartholomew, M. Polyamine involvement in the growth of hormone-responsive and -resistant human breast cancer cells in culture. Cancer Res., 49: 1371-1376, 1989.
10. Thomas, T., and Thomas T. J. Estradiol control of ornithine decarboxylase in RNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications. Breast Cancer Res. Treat., 29: 189-201, 1993.
11. Skou, G., Mangold, G., Dexter, D., Von Hoff, D., Heck, K., and Tessman, D. The evaluation of difluoromethylornithine (DFMO) with and without tamoxifen against the MCF-7 human breast cancer xenograft. In: Proceedings of the 6th Annual Breast Cancer Symposium, July 1996, p. 23.
12. Meyskens, F. L., Gerner, E. W., Emerson, S., Pelot, D., Durbin, T., Doyle, K., and Lagerberg, W. Effect of α-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized double-blinded trial for colon cancer prevention. J. Natl. Cancer Inst., 90: 1212-1218, 1998.
13. Levin, V. A., Prados, M. D., Yung, W. K., Gleason, M. J., Ictah, S., and Malec, M. Treatment of recurrent gliomas with eflornithine. J. Natl. Cancer Inst., 18: 1432-1437, 1992.
14. 1 to S transition. Exp. Cell Res., 131: 209-216, 1981.
15. Hayward, J. L., Carbone, P. P., Heuson, J. C., Kumaoka, S., Segaloff, A., and Rubers, R. D. Assessment of response to therapy in advanced breast cancer. A project of the programme on Clinical Oncology of International Union Against Cancer, Geneva, Switzerland. Cancer (Phila.), 39: 1289, 1977.
16. McCloskey, D. E., Casero, R. A., Woster, P. M., and Davidson, N. E. Induction of programmed cell death in human breast cancer cells by an unsymmetrical alkylated polyamine analogue. Cancer Res., 55: 3233-3236, 1995.
17. Kubota, S., Kiyopsawa, H., Nomura, Y., Yamada, T., and Segama, Y. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J. Natl. Cancer Inst., 89: 567-571, 1997.
18. Wallon, U. M., Shassetz, L. R., Cress, A. E., Bowden, G. T., and Gerner, E. W. Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer cell line. Mol. Carcinog., 11: 134-144, 1994.
19. Smith, M. K., Goral, M. A., Wreight, J. H., Matrisian, L. M., Morris, R. J., Klein-Szanto, A. J., and Gilmour, S. K. Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res., 57: 2104-2108, 1997.
20. Sunkara, P. S., and Rosenberger, A. L. Antimetastatic activity of DL-α-difluoromethyl-ornithine, an inhibitor of polyamine biosynthesis, in mice. Cancer Res., 47: 933-935, 1987.
21. Love, R. R., Carbone, P. P., Verma, A. K., Gilmore, D., Carey, P., Tutsch, K. D., Pomplum, M., and Wilding, G. Randomized Phase I chemoprevention dose-seeking study of α-difluoromethylornithine. J. Natl. Cancer Inst., 85: 732-737, 1993.
22. Abeloff, M. D., Slavik, M., Luk, G. D., Griffin, L. A., Hermann, J., Blanc, O., Sjoerdsma, A., and Baylin, S. B. Phase I trial and pharmacokinetic studies of α-di-fluoromethylornithine - an inhibitor of polyamine biosynthesis. J. Clin. Oncol., 2: 124-130, 1984.
23. Boiko, I. V., Mitchell, M. F., Pandey, D. K., White, R. A., Hu, W., Malpica, A., Nishioka, K., Boone, C. W., Atkinson, E. N., and Hittelman, W. N. DNA image cytometric measurement as a surrogate end point biomarker in a Phase I trial of α-difluoromethylornithine for cervical intra-epithelial neoplasia. Cancer Epidemiol. Biomark. Prev., 6: 849-855, 1997.
24. Gerner, E. W., Garewal, H. S., Emerson, S. S., and Sampliner, R. E. Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with α-difluoromethylornithine. Cancer Epidemiol. Biomark. Prev., 3: 325-330, 1994.
25. Pendyala, I., Creaven, P. J., and Porter, C. W. Urinary and erythrocyte polyamines during the evaluation of oral α-difluoromethylornithine in a Phase I chemoprevention clinical trial. Cancer Epidemiol. Biomark. Prev., 2: 235-241, 1993.
26. Haegele, K. D., Aiken, R. G., Grove, J., Schechter, P. J., and Koch-Weser, J. Kinetics of α-di-fluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin. Pharmacol. Ther., 30: 210-217, 1981.
27. Barranco, S. C., Ford, P. J., and Townsend, C. M., Jr. Heterogeneous survival and cell kinetics responses of human astrocytoma clones to difluoromethylornithine in vitro. Investig. New Drugs 7: 155-161, 1989.
28. Meyskens, F. L., and Gerner, E. W. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res., 5: 945-951, 1999.